



edap tms
Bringing New Horizons to Therapy

EDAP TMS SA to Announce Third Quarter 2023 Financial Results on November 9, 2023

Oct 26, 2023

Company to host conference call and webcast on Thursday, November 9th at 8:30am EDT

LYON, France, October 26, 2023 -- EDAP TMS SA (Nasdaq: EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the third quarter ended September 30th, 2023, before the markets open on Thursday, November 9th, 2023.

An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, François Dietsch, Chief Financial Officer and Ken Mobeck, Chief Financial Officer of the U.S. subsidiary. The call will be held at 8:30am EDT on Thursday, November 9th, 2023. Please refer to the information below for conference call dial-in information and webcast registration.

Call Details:

Date: Thursday, November 9th
Time: 8:30am EDT
Domestic: 1-877-451-6152
International: 1-201-389-0879
Passcode: 13741382
CallMe™ [LINK](#) (active 15 minutes prior to conference call)
Webcast: https://viaavid.webcasts.com/starthere.jsp?ei=1635563&tp_key=28f6dfe71c

About EDAP TMS SA

A recognized leader in the global therapeutic ultrasound market. EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit <http://www.edap-tms.com>, us.hifu-prostate.com and www.focalone.com.

Company Contact

Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com

Investor Contact

John Fraunces
LifeSci Advisors, LLC
(917) 355-2395
jfraunces@lifesciadvisors.com